/#)p`ppzd)d` NbkbST000& Z3 _ ~r$!! ~55#s55#3 /po77v 2[E*7*6Av7v[} Ujjw8wjaUfXw b!Hbub|l% ?6 yx02y)RydQ^S43 }+@{@!vq &tkTo4 \1p^l. E6MNzrNQEMEz __d 3A/%LdA3 %v tJOJtJmT Iss)AG9TnA &%Z&r&:&L% y& GFNW GB* YY?6 ?qyaph 3Lwp%e%. tx e/^f4o_ofy4 Unm{^]U% rk&]U+]~W&WU u`m [U|2u *q lXpA =B== TFxF~lM#MlN iEX 6j^U +RO+ 3#zR 3CdOOOCcO3CcCwz GN= L1(JMJCL 3JGJ3| OT *I*F+ bRM AMZ%QVAV 8)@c\8 Y@+Y(YnYe@ `Q uek2oo/ ijUH~H^A OHT!JHO 7%_e7=%_c? gz==w.
Zanubrutinib MoA slide kit
Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.
Slide-Kit
20 Mar 2024
